Bicycle Therapeutics plc (BCYC)

Market Cap	251.97M -55.2%
Revenue (ttm)	61.21M +217.4%
Net Income	-190.41M
EPS	-2.74
Shares Out	69.99M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	411,542
Open	3.510
Previous Close	3.510
Day's Range	3.500 - 3.640
52-Week Range	3.330 - 9.080
Beta	1.68
Analysts	Buy
Price Target	9.50 (+163.89%)
Est. Earnings	Oct 29, 2026

About BCYC

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company’s products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted imm...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 23, 2019
• Employees: 288
• Stock Exchange: Nasdaq
• Ticker Symbol: BCYC
• Website: https://www.bicycletherapeutics.com

Financial Performance

In 2025, Bicycle Therapeutics's revenue was $72.59 million, an increase of 105.77% compared to the previous year's $35.28 million. Losses were -$218.96 million, 29.5% more than in 2024.

Analyst Summary

According to 9 analysts, the average rating for BCYC stock is "Buy." The 12-month stock price target is $9.5, which is an increase of 163.89% from the latest price.

Price Target

$9.5

(163.89% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 16, 2026

Data Sources Report a data error